

Robert Greene Steme Jorge A. Goldstein David K.S. Cornwell Robert W. Esmond Tracy-Gene G. Durkin Michale B. Ray Robert E. Sokohl Eric K. Steffe Michael O. Lee John M. Covert Robert C. Millonig Donald J. Featherstone Timothy J. Shea, Ir Michael V. Messinger Judith U. Kim Jeffrey T. Helvey Eldora L. Ellison Onald R. Banowit

Petre A. Jackman Brian I. Del Buono Mark Fox Evens Vincent L. Capuano Elizabeth I. Haanes Michael D. Specht Kevin W. McCabe Glenn J. Perry Edward W. Yee Grant E. Reed Virgü Lee Beaston Theodore A. Wood Joseph S. Ostroff Jason D. Eisenberg Iravy L. Muller Jon E. Whight LuAnne M. DeSantis Ann E. Surmerfield

Cymthia M. Bouchez Imnothy A. Doyle Gaby L. Longsworth Lori A. Gordon Laura A. Vogel Bryan S. Wade Baschir M.S. Ali Shamnon A. Carroll Anthar F. Khal Michelle K. Holoubek Marsha A. Rose Scott A. Schaller Lei Zhou W. Blake Coblentz* James J. Pohl John T. Haran Mark W. Rygiel Michael R. Malek* Carla Ji-Eun Kim Doyle A. Siever* Unixe Winkler Bryan L. Skelton* Paul A. Calvo Robert A. Schwartzman C. Matthew Rozier Alexandra K. Pechhold

Registered Patent Agents • Karen R. Markowicz Matthew J. Dowd Katrina Yujian Pei Quach Julie A. Heider Mita Mukherjee

Attn: Mail Stop Amendment

Scott M. Woodhouse Petter A. Socarras Jeffrey K. Mills Danielle L. Letting Lori Brandes Steven C. Oppenheimer Aaron S. Lukas Gaurav Asthana

Of Counsel Edward J. Kessler Kenneth C. Bass III Marvin C. Guthrie Christopher P. Wrist

*Admitted only in Manyland *Admitted only in Virginia •Practice Limited to Federal Agencies

March 18, 2008

WRITER'S DIRECT NUMBER: (202) 772-8625 INTERNET ADDRESS: ESTEFFE@SKGF.COM

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Utility Patent Application

Application No. 10/586,045; § 371 Filing Date: June 12, 2007

For:

Rapid Screening Method of Translational Fusion Partners for

Producing Recombinant Proteins and Translational Fusion Partners

Screened Therefrom

Inventors:

SOHN et al.

Our Ref:

2472.0010000/EKS/BNC

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Information Disclosure Statement Under 37 C.F.R. § 1.97(b);
- 2. One (1) page of Form PTO/SB/08A citing sixteen (16) documents;
- 3. A copy of seven (7) of the cited documents FP1-FP7;
- 4. Four (4) pages of Form PTO/SB/08B citing forty documents;
- 5. A copy of the forty (40) cited documents NPL1-NPL40; and
- 6. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier.

In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Commissioner for Patents March 18, 2008 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Eric K. Steffe

Attorney for Applicants Registration No. 36,688

EKS/BNC/las Enclosures

794978_1.DOC

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

SOHN et al.

Appl. No.: 10/586,045

Int'l Filing Date: December 30, 2004

§371 Date: June 12, 2007

For: Rapid Screening Method of

Translational Fusion Partners for Producing Recombinant Proteins

and Translational Fusion
Partners Screened Therefrom

Confirmation No.: 2495

Art Unit:

1632

Examiner:

To be assigned

Atty. Docket: 2472.0010000/EKS/BNC

Information Disclosure Statement Under 37 C.F.R. § 1.97(b)

Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying IDS Forms, PTO/SB/08A and PTO/SB/08B, are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Copies of documents, FP1 to FP7 and NPL1 to NPL40, are submitted. However, in accordance with 37 C.F.R. § 1.98(a)(2), copies of U.S. patents and patent application publications, cited on the attached IDS Form PTO/SB/08A as documents US1 to US9, are not submitted.

The Examiner's attention is directed to the following commonly-owned copending U.S. application, which is directed to related technical subject matter:

Application No. 11/914,437 inventors Sohn, et al., filed July 13, 2006, U.S. National Phase of PCT/IB2006/003102 (listed as document **FP7**); the unpublished Preliminary Amendment to this application is listed as document **NPL38**.

The identification of U.S. Patent Applications and related documents is not to be construed as a waiver of secrecy as to those applications now or upon issuance of the present application as a patent. The Examiner is respectfully requested to consider the cited applications and the documents cited therein during examination.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached IDS Forms based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent

application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed IDS Forms, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Eric K. Steffe

Attorney for Applicants Registration No. 36,688

Data

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

787277 1